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BACKGROUND
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chime-
ric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory 
large B-cell lymphoma after the failure of conventional therapy.
METHODS
In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell 
lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lympho-
ma who had refractory disease despite undergoing recommended prior therapy. Pa-
tients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body 
weight after receiving a conditioning regimen of low-dose cyclophosphamide and 
fludarabine. The primary end point was the rate of objective response (calculated as 
the combined rates of complete response and partial response). Secondary end points 
included overall survival, safety, and biomarker assessments.
RESULTS
Among the 111 patients who were enrolled, axi-cel was successfully manufactured 
for 110 (99%) and administered to 101 (91%). The objective response rate was 82%, 
and the complete response rate was 54%.With a median follow-up of 15.4 months, 
42% of the patients continued to have a response, with 40% continuing to have a 
complete response. The overall rate of survival at 18 months was 52%. The most com-
mon adverse events of grade 3 or higher during treatment were neutropenia (in 
78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3 
or higher cytokine release syndrome and neurologic events occurred in 13% and 
28% of the patients, respectively. Three of the patients died during treatment. Higher 
CAR T-cell levels in blood were associated with response.
CONCLUSIONS
In this multicenter study, patients with refractory large B-cell lymphoma who received 
CAR T-cell therapy with axi-cel had high levels of durable response, with a safety pro-
file that included myelosuppression, the cytokine release syndrome, and neurologic 
events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy 
Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216.)
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L arge B-cell lymphomas, including diffuse large B-cell lymphoma, primary me-diastinal B-cell lymphoma, and transformed 
follicular lymphoma, are treated with combination 
chemoimmunotherapy at diagnosis.1-3 Patients who 
have a relapse with chemotherapy-sensitive dis-
ease may be treated with high-dose chemotherapy 
followed by autologous stem-cell transplantation.1-3 
However, patients who have disease that is resis-
tant to primary or salvage chemoimmunotherapy 
or who have had a relapse after transplantation 
have an extremely poor prognosis.4-13 Recently, in 
a large, international, retrospective research study 
involving patients with non-Hodgkin’s lymphoma 
(SCHOLAR-1), investigators found an objective 
response rate of 26%, a complete response rate 
of 7%, and a median overall survival of 6.3 months 
with existing therapies among patients who had 
aggressive B-cell lymphoma that was resistant 
to chemotherapy or who had a relapse within 
12 months after autologous stem-cell transplan-
tation.14
Single-institution studies of anti-CD19 chime-
ric antigen receptor (CAR) T-cell therapy have 
shown high response rates in refractory B-cell 
lymphomas after the failure of conventional ther-
apy.15-19 Investigators at the National Cancer Insti-
tute have found that many responses have been 
ongoing beyond 4 years, which suggests that this 
therapy may be potentially curative.15-17 Axicabta-
gene ciloleucel (axi-cel, Kite Pharma) is an autolo-
gous anti-CD19 CAR T-cell therapy that uses the 
same CAR construct that was developed at the 
National Cancer Institute.15-17,20 It consists of a 
single-chain variable fragment extracellular do-
main targeting CD19 proteins with CD3ζ (also 
called CD247) and CD28 intracellular domains that 
signal T-cell activation.20 In this therapy, T cells 
that have been removed from a patient are geneti-
cally engineered to express anti-CD19 CARs and 
are then injected back into the patient.
A phase 1 multicenter study (ZUMA-1) involv-
ing seven patients with refractory large B-cell 
lymphoma showed that axi-cel could be centrally 
manufactured and safely administered.21 An over-
all response to axi-cel therapy was reported in five 
patients and a complete response in four patients, 
with an ongoing complete response in three pa-
tients reported at 1 year.21 Here, we report the 
results of the primary analysis of phase 2 of 
ZUMA-1 and an updated analysis with 1 year of 
follow-up.
Me thods
Patients and Study Design
The study was approved by the institutional re-
view board at each study site and was conducted 
in accordance with the Good Clinical Practice 
guidelines of the International Conference on 
Harmonisation. All the patients provided writ-
ten informed consent. The study was designed 
by employees of Kite Pharma, which also paid 
for medical-writing support. All the authors dis-
cussed and interpreted the results and vouch for 
the completeness and accuracy of the data and 
analyses and for the adherence of the study to 
the protocol, available with the full text of this 
article at NEJM.org. All the authors contributed 
to the conduct of the study, data analyses, and 
writing of the manuscript.
The phase 2 treatment portion of the study 
ran from November 2015 through September 
2016 at 22 study centers (21 in the United States 
and 1 in Israel). (A complete list of study sites is 
provided in the Supplementary Appendix, avail-
able at NEJM.org.) Follow-up to evaluate the 
duration of response, survival, and late adverse 
events is ongoing.
All the patients had histologically confirmed 
large B-cell lymphoma, including diffuse large 
B-cell lymphoma (cohort 1) and primary medias-
tinal B-cell lymphoma or transformed follicular 
lymphoma (cohort 2), on the basis of the 2008 
World Health Organization guidelines.22 Central 
confirmation of the diagnosis was performed 
retrospectively. Patients had refractory disease, 
which was defined as progressive or stable dis-
ease as the best response to the most recent 
chemotherapy regimen or disease progression or 
relapse within 12 months after autologous stem-
cell transplantation. Eligibility criteria and ther-
apy were similar to those in the phase 1 study 
(see the Methods section in the Supplementary 
Appendix).21
After leukapheresis and axi-cel manufactur-
ing, patients received fixed low-dose condition-
ing chemotherapy consisting of fludarabine (at a 
dose of 30 mg per square meter of body-surface 
area per day) and cyclophosphamide (at a dose 
of 500 mg per square meter per day) on days −5, 
−4, and −3 before the administration of a single 
intravenous infusion of axi-cel at a target dose of 
2×106 CAR T cells per kilogram of body weight 
(on day 0).21 Systemic bridging chemotherapy was 
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not allowed after leukapheresis and before the 
administration of axi-cel. Patients who had an 
initial response and then had disease progression 
at least 3 months after the first dose of axi-cel 
could be retreated.
End Points and Assessments
The primary end point was the rate of objective 
response (calculated as the combined rates of com-
plete response and partial response), as assessed by 
the investigators according to the International 
Working Group Response Criteria for Malignant 
Lymphoma.23 Secondary end points included the 
duration of response, progression-free survival, 
overall survival, incidence of adverse events, and 
blood levels of CAR T cells and serum cytokines. 
The cytokine release syndrome was graded ac-
cording to the criteria of Lee et al.24 We used the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.03, to grade 
symptoms of the cytokine release syndrome and 
neurologic events along with other adverse events. 
CAR T-cell expansion and serum cytokines, and 
their associations with clinical outcomes, were 
analyzed as described previously.21,25 The cell-of-
origin subtype was assessed centrally by means 
of the NanoString Lymphoma Subtyping Test.26 
Details regarding the response criteria, grading of 
the cytokine release syndrome, and calculation 
of the CD19 histologic score are provided in the 
Methods section in the Supplementary Appendix.
Statistical Analysis
The primary analysis was conducted at the point 
when 92 patients could be evaluated 6 months 
after the axi-cel infusion. Efficacy and safety 
analyses were reported in the modified intention-
to-treat population of all the patients who had 
received axi-cel. We also performed an updated 
analysis of all the patients who had been treated 
in phase 121 and phase 2 of ZUMA-1.
To analyze the response rate, we used a single-
group design in which we compared the response 
of patients with a prespecified rate of response 
of 20% on the basis of historical values for refrac-
tory diffuse large B-cell lymphoma.4-12 Efficacy 
testing had a power of at least 90% to distinguish 
between an active therapy with a 40% true re-
sponse rate and a therapy with a response rate 
of 20% or less with the use of a one-sided alpha 
level of 0.025. The primary end point was tested 
with an exact binomial test. We used the Wilcoxon 
rank-sum test to measure the associations between 
outcomes and levels of CAR T cells and cytokines, 
with P values adjusted using Holm’s procedure. 
Confidence intervals were calculated with the use 
of the Clopper–Pearson method.
R esult s
Patients
A total of 111 patients were enrolled in the study. 
Axi-cel was manufactured for 110 patients (99%) 
and administered to 101 patients (91%); the latter 
population was included in the modified inten-
tion-to-treat analysis. Patients included 77 with 
diffuse large B-cell lymphoma and 24 with pri-
mary mediastinal B-cell lymphoma or transformed 
follicular lymphoma (Table 1, and Fig. S1 in the 
Supplementary Appendix). The date of data cutoff 
for the primary analysis was January 27, 2017; the 
median follow-up was 8.7 months. The cutoff date 
for the updated analysis was August 11, 2017, 
which resulted in a median follow-up of 15.4 
months.
The median time from leukapheresis to deliv-
ery of axi-cel to the treatment facility was 17 days. 
Of the 10 patients who did not receive axi-cel, 
1 had unsuccessful manufacture of the CAR T-cell 
product, 4 had adverse events, 1 died from disease 
progression, and 2 had nonmeasurable disease 
before conditioning chemotherapy. After condi-
tioning chemotherapy but before axi-cel infusion, 
1 patient had sepsis and 1 died from multiple 
factors with laboratory abnormalities suggestive 
of the tumor lysis syndrome, gastrointestinal 
bleeding and perforation, and disease progression.
Among the patients who were treated with 
axi-cel, the median age was 58 years (range, 23 
to 76). Most of the patients (85%) had stage III or 
IV disease; 77% had disease that was resistant to 
second-line or later therapies, 21% had disease 
relapse after transplantation, 69% had received at 
least three previous therapies, and 26% had a 
history of primary refractory disease (Table 1).
Efficacy
Primary Analysis
At a minimum of 6 months of follow-up, the objec-
tive response rate among the protocol-specified 
92 patients was 82% (95% confidence interval [CI], 
72 to 89; P<0.001 for the comparison with a 20% 
historical control rate); among these patients, the 
complete response rate was 52% (Table S1 in the 
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Supplementary Appendix). An additional 9 pa-
tients were enrolled and awaiting treatment at 
the time that the 92nd patient received the axi-
cel infusion. Among the 101 patients who received 
axi-cel, the objective response rate was 82% (95% 
CI, 73 to 89), with a 54% complete response rate 
(Fig. 1A, and Fig. S2 in the Supplementary Ap-
pendix).
The median time to response was rapid (1.0 
month; range, 0.8 to 6.0). The median duration 
of response was 8.1 months (95% CI, 3.3 to could 
not be estimated). Response rates were consistent 
across key covariates, including age, disease stage, 
International Prognostic Index score at enrollment, 
presence or absence of bulky disease, cell-of-
origin subtype, and use of tocilizumab or gluco-
Variable
Patients with 
DLBCL
Patients with 
PMBCL or TFL All Patients
Treatment disposition
No. of patients enrolled 81 30 111
Treatment with axi-cel — no. (%)
Yes 77 (95) 24 (80) 101 (91)
No 4 (5) 6 (20) 10 (9)
Death before treatment† 1 (1) 2 (7) 3 (3)
Adverse event‡ 3 (4) 2 (7) 5 (5)
Other§ 0 2 (7) 2 (2)
Characteristics at baseline
No. of patients 77 24 101
Disease type — no. (%)
DLBCL 77 (100) 0 77 (76)
PMBCL 0 8 (33) 8 (8)
TFL 0 16 (67) 16 (16)
Age
Median (range) — yr 58 (25–76) 57 (23–76) 58 (23–76)
≥65 yr — no. (%) 17 (22) 7 (29) 24 (24)
Male sex — no. (%) 50 (65) 18 (75) 68 (67)
ECOG performance-status score of 1  
— no. (%)
49 (64) 10 (42) 59 (58)
Disease stage — no. (%)
I or II 10 (13) 5 (21) 15 (15)
III or IV 67 (87) 19 (79) 86 (85)
International Prognostic Index score  
— no. (%)¶
0–2 40 (52) 13 (54) 53 (52)
3 or 4 37 (48) 11 (46) 48 (48)
CD-19 status — no./total no. (%)‖
Negative 7/63 (11) 1/19 (5) 8/82 (10)
Positive 56/63 (89) 18/19 (95) 74/82 (90)
Prior therapies — no. (%)
≥Three prior lines of therapy 49 (64) 21 (88) 70 (69)
History of primary refractory disease** 23 (30) 3 (12) 26 (26)
History of resistance to two consecu-
tive lines
39 (51) 15 (62) 54 (53)
Table 1. Treatment Disposition and Baseline Characteristics of the Patients.*
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corticoids. Responses were also consistent in 26 
patients who had a history of primary refractory 
disease (response rate, 88%) and in 21 patients 
who had a history of autologous stem-cell trans-
plantation (response rate, 76%). The response 
rates did not appear to be influenced by biologic 
covariates, such as the prevalence and intensity 
of CD19 expression, or by product characteris-
tics, such as the ratio of CD4 cells to CD8 cells 
and T-cell phenotypes (Fig. 1B, and Tables S2, 
S3, and S4 in the Supplementary Appendix).
At the time of the primary analysis, 52 patients 
had disease progression, 3 patients had died from 
adverse events during treatment, 1 patient started 
an alternative therapy before disease progres-
sion, 44 remained in remission (of whom 39 had 
a complete response), and 1 had stable disease. 
Of the patients who had disease progression after 
an initial response, 9 were retreated with axi-cel, 
according to the protocol. Of these patients, 5 had 
a response (2 complete and 3 partial), and 2 of 
these patients had an ongoing response.
Updated Analysis
To evaluate the durability of response with axi-cel, 
we performed an updated analysis when the 108 
patients in the phase 1 and 2 portions of ZUMA-1 
had been followed for a minimum of 1 year. The 
objective response rate was 82%, including a com-
plete response rate of 58%. Of the patients who 
did not have a complete response at the time of 
the first tumor assessment (1 month after the 
infusion of axi-cel), 23 patients (11 of 35 with a 
partial response and 12 of 25 with stable disease) 
subsequently had a complete response in the ab-
sence of additional therapies as late as 15 months 
after treatment. At the data cutoff, 42% remained 
in response, including 40% with a complete re-
sponse. Of the 7 patients in phase 1 of the study, 
3 had an ongoing complete response at 24 months.
Preliminary analysis of CD19 expression at 
baseline and at the time of disease progression was 
ongoing. Of the 11 patients with disease pro-
gression who were included in the analysis, 3 (27%) 
with CD19-positive status at baseline had CD19-
negative disease at time of disease progression.
Ongoing response rates were consistent across 
key covariates, including the use of tocilizumab 
or glucocorticoids (Fig. S3 in the Supplementary 
Appendix). The median duration of response was 
11.1 months (95% CI, 3.9 to could not be esti-
mated) (Fig. 2A). The median duration of pro-
gression-free survival was 5.8 months (95% CI, 
3.3 to could not be estimated) (Fig. 2B), with pro-
gression-free survival rates of 49% (95% CI, 39 to 
58) at 6 months, 44% (95% CI, 34 to 53) at 12 
months, and 41% (95% CI, 31 to 50) at 15 months. 
The median overall survival was not yet reached 
Variable
Patients with 
DLBCL
Patients with 
PMBCL or TFL All Patients
Refractory subgroup at study entry — no. (%)
Primary refractory 2 (3) 0 2 (2)
Refractory to second-line or subsequent 
therapy
59 (77) 19 (79) 78 (77)
Relapse after autologous stem-cell trans-
plantation
16 (21) 5 (21) 21 (21)
*  The abbreviation axi-cel denotes axicabtagene ciloleucel, DLBCL diffuse large B-cell lymphoma, ECOG Eastern 
Cooperative Oncology Group, PMBCL primary mediastinal large B-cell lymphoma, and TFL transformed follicular 
lymphoma.
†  Two patients died from disease progression (one after unsuccessful manufacture of the CAR T-cell product) and one 
from the tumor lysis syndrome.
‡  The adverse events in the four patients who had undergone leukapheresis but had not received conditioning therapy 
or axi-cel were small intestine obstruction, hypoxia and pleural effusion, spinal column stenosis, and deep-vein 
thrombosis. The remaining patient received conditioning therapy but had a skin and wound infection that led to ec-
thyma and sepsis before axi-cel treatment.
§  The two patients in this category had nonmeasurable disease after leukapheresis.
¶  Scores on the International Prognostic Index include low risk (0 or 1 point), low-intermediate risk (2 points), high- 
intermediate risk (3 points), and high risk (4 or 5 points).
‖  The CD19 histologic score was assessed in the 82 patients with available samples.
**  Patients may have had other therapies after primary refractory disease.
Table 1. (Continued.)
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Objective Response Rate
Overall
Refractory subgroup
Refractory to ≥second-line therapy
Relapse after ASCT
Age
<65 yr 
≥65 yr 
Disease stage
I or II 
III or IV 
IPI risk score
0–2 
3 or 4 
Extranodal disease
Yes 
No 
Bulky disease (≥10 cm)
Yes 
No 
Treatment history
Primary refractory disease
Refractory to two consecutive lines
CD19 status
Positive
Negative 
CD19 histologic score
≤150
>150
Cell of origin
Germinal center B-cell–like subtype
Activated B-cell–like subtype
CD4:CD8  ratio
>1
≤1
Tocilizumab use
Yes 
No 
Glucocorticoid  use
Yes
No
No. of Patients
Who Could
Be Evaluated Objective Response Rate (95% CI)Subgroup
101
78
21
77
24
15
86
53
48
70
31
17
84
26
54
74
8
26
56
49
17
47
52
43
58
27
74
No. of Patients
with Event
83
65
16
61
22
13
70
46
37
56
27
12
71
23
42
63
6
22
47
43
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41
40
36
47
21
62
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es
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)
100
80
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70
60
40
30
10
50
20
0
ORR SD PD NE
DLBCL (N=77)
ORR SD PD NE
PMBCL or TFL (N=24)
ORR SD PD NE
All Patients (N=101)
Partial response
Stable disease
Disease progression
Could not be evaluated
Complete response
B Subgroup Analysis 
A Objective Response Rate
82
12
(9) 5
(4) 1
(1)
83
8
(2) 4
(1)
4
(1)
82
11
(11) 5
(5)
2
(2)
49
(38)
32
(25)
71
(17)
12
(3)
54
(55)
28
(28)
0.0
0.82 (0.73–0.89)
0.83 (0.73–0.91) 
0.76 (0.53–0.92)
0.79 (0.68–0.88)
0.92 (0.73–0.99)
0.87 (0.60–0.98)
0.81 (0.72–0.89)
0.87 (0.75–0.95)
0.77 (0.63–0.88)
0.80 (0.69–0.89)
0.87 (0.70–0.96)
0.71 (0.44–0.90)
0.85 (0.75–0.91)
0.88 (0.70–0.98)
0.78 (0.64–0.88)
0.85 (0.75–0.92)
0.75 (0.35–0.97)
0.85 (0.65–0.96)
0.84 (0.72–0.92)
0.88 (0.75–0.95)
0.76 (0.50–0.83)
0.87 (0.74–0.95)
0.77 (0.63–0.87)
0.84 (0.69–0.93)
0.81 (0.69–0.90)
0.78 (0.58–0.91)
0.84 (0.73–0.91)
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(95% CI, 12.0 months to could not be estimated) 
(Fig. 2C), with overall survival rates of 78% (95% 
CI, 69 to 85) at 6 months, 59% (95% CI, 49 to 68) 
at 12 months, and 52% (95% CI, 41 to 62) at 18 
months. A total of 56% of patients remained alive 
at the time of the data cutoff. Two patients who 
had a response underwent allogeneic stem-cell 
transplantation.
Safety
Primary Analysis
During treatment, all 101 patients who had re-
ceived axi-cel had adverse events, which were grade 
3 or higher in 95% (Table 2). The most common 
adverse events of any grade were pyrexia (in 85% 
of the patients), neutropenia (in 84%), and ane-
mia (in 66%). The most common adverse events 
of grade 3 or higher were neutropenia (in 78%), 
anemia (in 43%), and thrombocytopenia (in 38%). 
The cytokine release syndrome occurred in 94 
patients (93%). Most cases were of low grade (37% 
of grade 1 and 44% of grade 2), with 13% of grade 
3 or higher (9% of grade 3, 3% of grade 4, and 
1% of grade 5).
The most common symptoms of the cytokine 
release syndrome of grade 3 or higher were py-
rexia (in 11% of the patients), hypoxia (in 9%), 
and hypotension (in 9%). Vasopressors were used 
in 17% of the patients. The median time after 
infusion until the onset of the cytokine release 
syndrome was 2 days (range, 1 to 12), and the 
median time until resolution was 8 days. All the 
events associated with the cytokine release syn-
drome resolved except for one event of grade 5 
hemophagocytic lymphohistiocytosis. Another 
event of grade 5 cardiac arrest occurred in a 
patient with the cytokine release syndrome.
Neurologic events occurred in 65 patients (64%); 
28% were grade 3 or higher. The most common 
neurologic events of grade 3 or higher were en-
cephalopathy (in 21% of the patients), confusional 
state (in 9%), aphasia (in 7%), and somnolence (in 
7%). Early neurologic signs included word-finding 
difficulties (dysphasia), attention or calculation 
defects (counting backward by serial 7s), and dif-
ficulty executing complex commands (handwrit-
ing).27 The median onset of neurologic events 
occurred on day 5 (range, 1 to 17), with median 
resolution on day 17 after infusion. One patient 
had ongoing grade 1 memory impairment that re-
solved after the data cutoff for the primary analy-
sis. All the other neurologic events resolved except 
for four events, which were ongoing at the time 
of death (two deaths from progressive disease 
and two from adverse events unrelated to neuro-
logic events). Rates of the cytokine release syn-
drome and neurologic events decreased over the 
course of the study (Table S5 in the Supplemen-
tary Appendix). Forty-three percent of patients 
received tocilizumab and 27% received glucocor-
ticoids for the management of the cytokine re-
lease syndrome, neurologic events, or both,24 with 
no apparent effect on overall or ongoing response 
rates (Fig. 1B, and Fig. S3 in the Supplementary 
Appendix).
Updated Analysis
Ten patients had serious adverse events (includ-
ing nine infections in 8 patients) after the data 
cutoff for the primary analysis (Table S6 in the 
Supplementary Appendix). There were no new 
events associated with the cytokine release syn-
drome or neurologic events related to axi-cel treat-
ment. Forty-four patients (44%) died from causes 
that included disease progression (in 37 patients), 
adverse events (in 3 patients, including 2 with the 
above-mentioned axi-cel–related events associated 
Figure 1 (facing page). Objective Response Rate  
among the 101 Treated Patients.
Panel A shows the objective response rate (ORR; cal-
culated as complete response [CR] plus partial re-
sponse [PR]) among the patients who received axi-
cabtagene ciloleucel (axi-cel), an anti-CD19 chimeric 
antigen receptor T-cell therapy, as well as the response 
among the patients with stable disease (SD), disease 
progression (PD), and those who could not be evaluat-
ed (NE). The patients in the modified intention-to-
treat population were evaluated according to the two 
main disease cohorts: diffuse large B-cell lymphoma 
(DLBCL) and either primary mediastinal large B-cell 
lymphoma (PMBCL) or transformed follicular lympho-
ma (TLF). The numbers in parentheses indicate the 
number of patients who had the specified response. 
On independent central review, the objective response 
rate was 71%, including a complete response rate of 
51% and a partial response rate of 20%. Panel B 
shows the subgroup analysis of the objective response 
rate for key baseline and clinical covariates. Scores on 
the International Prognostic Index (IPI) include low 
risk (0 or 1 point), low-intermediate risk (2 points), 
high-intermediate risk (3 points), and high risk (4 or  
5 points). The 95% confidence interval (CI) was calcu-
lated with the use of the Clopper–Pearson method. 
ASCT denotes autologous stem-cell transplantation.
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with the cytokine release syndrome and 1 with 
pulmonary embolism that was not related to axi-
cel), and other causes after disease progression 
and subsequent therapies that were not related to 
axi-cel (in 4). One death that was not associated 
with axi-cel was previously reported in phase 1 of 
ZUMA-1.21 There were no new deaths from ad-
verse events after the primary analysis. No cases 
of replication-competent retrovirus or axi-cel treat-
ment-related secondary cancers were reported.
Biomarkers
CAR T levels peaked in the peripheral blood 
within 14 days after infusion of axi-cel and were 
detectable in most patients at 180 days after in-
fusion (Fig. 3A). Three patients with ongoing 
complete remission at 24 months still had detect-
able CAR T levels in the blood. Expansion was 
significantly associated with response (P<0.001), 
with an area under the curve within the first 28 
days after treatment that was 5.4 times as high 
among the patients who had a response as among 
those who did not have a response. Peak expan-
sion and area under the curve were significantly 
associated with neurologic events of grade 3 or 
higher but not with the cytokine release syndrome 
(Fig. 3B, and Table S7 and Fig. S4 in the Supple-
mentary Appendix). Of 44 serum biomarkers 
that were examined, several biomarkers, includ-
ing interleukin-6, -10, -15, and -2Rα and granzyme 
B, were significantly associated with neurologic 
events and the cytokine release syndrome of 
grade 3 or higher (Table S8 in the Supplementary 
Appendix). Several biomarkers, including interleu-
kin-2, granulocyte–macrophage colony-stimulat-
ing factor (GM-CSF), and ferritin, were signifi-
cantly associated only with neurologic events of 
grade 3 or higher (Fig. 3C). The induction of anti-
CAR antibodies was not observed in any patient.
Discussion
In this multicenter, phase 2 trial of axi-cel therapy, 
82% of the 101 patients with refractory large B-cell 
lymphoma who were treated had an objective re-
sponse, and 54% had a complete response. These 
findings compare favorably with the results of 
the recent SCHOLAR-1 study of existing therapies 
for this disease, which showed an objective re-
sponse rate of 26% and a complete response rate 
of 7%.14 With a median follow-up of 15.4 months 
in our study, responses were ongoing in 42% of the 
patients, including in 40% who had a complete 
response, with the emergence of a plateau in the 
duration of the response curve at 6 months. Al-
though most responses occurred in the first 
month, 23 patients had a complete response as late 
as 15 months. It would be reasonable to monitor 
patients who did not have a complete response at 
the first disease assessment and allow for an op-
portunity for an improved response, since consoli-
dation with allogeneic stem-cell transplantation 
comes with a high rate of treatment-related death 
and would also ablate CAR T cells. The median 
overall survival had not been reached, with an 
overall survival rate at 18 months of 52%. Ongo-
ing durable remissions have been observed in pa-
tients at 24 months. These results, combined with 
the observation of ongoing long-term remissions 
beyond 4 years in the previous National Cancer 
Institute study,17 suggest that axi-cel provides sub-
stantial clinical benefit for patients with refractory 
disease.
In our study, the responses to treatment, in-
cluding ongoing ones, were consistent across key 
covariates. Similar response rates were observed 
in the 8 patients with CD19-negative disease as 
in those with CD19-positive disease at baseline, 
which suggests the potential limitations in CD19 
detection rather than true CD19 negativity. Analy-
ses of product characteristics, including the ratio 
of CD4 cells to CD8 cells and T-cell phenotypes, 
also showed similar outcomes, which further 
Figure 2 (facing page). Kaplan–Meier Estimates of the 
Duration of Response, Progression-free Survival, and 
Overall Survival.
Panel A shows the duration of response, according to 
investigator assessment, in the 89 study patients who 
had an objective response, including those with a com-
plete response and those with a partial response. Pa-
tients who had a complete response had a longer dura-
tion of response than those with an objective or partial 
response. According to independent central review, the 
median duration of response was 8.1 months (range, 
3.5 to could not be estimated [NE]). Panel B shows the 
rate of progression-free survival, and Panel C the rate 
of overall survival in the 108 patients who were treated 
in the phase 1 and phase 2 studies. Tick marks indi-
cate the time of data censoring at the last follow-up. 
NR denotes not reached.
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highlights the consistency in treatment effects 
across clinical and biologic covariates. One limi-
tation of our study is the lack of a planned, de-
tailed analysis of molecular and cytogenetic char-
acteristics. Prospective data are needed on the 
influence of disease biology, such as double- and 
triple-hit lymphomas, on outcomes with CAR 
T-cell therapy.
To be successful, a personalized cell therapy 
must be delivered in a safe and timely manner. 
In this study, we confirmed the feasibility and 
reliability of centralized manufacturing and coor-
dination of leukapheresis procedures and ship-
ping from multiple centers across the country. 
The product was manufactured for 99% of the 
enrolled patients and was administered to 91%. 
Event Any Grade Grade 1 or 2 Grade ≥3
number of patients (percent)
Adverse event
Any 101 (100) 5 (5) 96 (95)
Pyrexia 86 (85) 72 (71) 14 (14)
Neutropenia 85 (84) 6 (6) 79 (78)
Anemia 67 (66) 24 (24) 43 (43)
Hypotension 60 (59) 46 (46) 14 (14)
Thrombocytopenia 59 (58) 21 (21) 38 (38)
Nausea 59 (58) 59 (58) 0
Fatigue 52 (51) 50 (50) 2 (2)
Decreased appetite 50 (50) 48 (48) 2 (2)
Headache 47 (47) 46 (46) 1 (1)
Diarrhea 43 (43) 39 (39) 4 (4)
Hypoalbuminemia 41 (41) 40 (40) 1 (1)
Hypocalcemia 40 (40) 34 (34) 6 (6)
Chills 39 (39) 39 (39) 0
Tachycardia 39 (39) 37 (37) 2 (2)
Febrile neutropenia 35 (35) 4 (4) 31 (31)
Encephalopathy 34 (34) 13 (13) 21 (21)
Thrombocytopenia 59 (58) 21 (21) 38 (38)
Vomiting 34 (34) 33 (33) 1 (1)
Hypokalemia 33 (33) 30 (30) 3 (3)
Hyponatremia 33 (33) 23 (23) 10 (10)
Constipation 31 (31) 31 (31) 0
White-cell count decreased 31 (31) 2 (2) 29 (29)
Cytokine release syndrome
Any 94 (93) 81 (80) 13 (13)
Pyrexia 77 (76) 66 (65) 11 (11)
Hypotension 41 (41) 32 (32) 9 (9)
Hypoxia 22 (22) 13 (13) 9 (9)
Tachycardia 21 (21) 20 (20) 1 (1)
Chills 20 (20) 20 (20) 0
Sinus tachycardia 8 (8) 8 (8) 0
Headache 5 (5) 5 (5) 0
Table 2. Adverse Events, the Cytokine Release Syndrome, and Neurologic Events Associated with Treatment.*
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The short 17-day median turnaround time was 
critical for these patients with refractory large 
B-cell lymphoma, who generally have rapidly 
growing disease.
We found that axi-cel could be administered 
safely at medical facilities that perform transplan-
tation, even if such centers had no experience in 
CAR T-cell therapy. Algorithms for the manage-
ment of the cytokine release syndrome and neu-
rologic events were effectively implemented. The 
incidence of the cytokine release syndrome and 
neurologic events of grade 3 or higher decreased 
over the course of the study, possibly because of 
increased experience at the study centers and a 
protocol amendment allowing for earlier admin-
istration of tocilizumab or glucocorticoids.27 The 
cytokine release syndrome and neurologic events 
were generally reversible with no clinical sequelae. 
With extended follow-up, there were no new un-
expected serious adverse events and no new onset 
of the cytokine release syndrome or neurologic 
events related to CAR T cells. Furthermore, the 
3% rate of death during treatment compares fa-
vorably with rates observed during allogeneic stem-
cell transplantation.28
CAR T-cell levels over the first 28 days of treat-
ment correlated with an objective response. This 
finding was consistent with prior single-institu-
tion trials of CAR T-cell therapy19,25 and strength-
ens the hypothesis that the presence of higher 
CAR T-cell levels after infusion may further aug-
ment efficacy. Recent studies have shown intrin-
sic differences in CAR T cells that use CD28 
rather than other costimulatory molecules, such 
as 4-1BB,29,30 but it remains unclear whether either 
costimulatory domain will confer differences in 
activity or persistence in patients and whether such 
responses are dependent on the tumor type.31 
Therefore, optimization of CAR constructs and 
manufacturing as well as combination strategies 
with immunomodulatory agents are being ex-
plored.
Serum biomarker analysis confirmed associa-
tions of the presence of interleukin-6, -15, and 
-2Rα, as well as other markers, with the cytokine 
release syndrome of grade 3 or higher19,32-35 and 
with neurologic events of grade 3 or higher.19,34 
However, CAR T-cell levels and specific cyto-
kines, including interleukin-2, GM-CSF, and fer-
ritin, were associated only with grade 3 or higher 
neurologic events, which suggests that distinct 
mechanisms may underlie the pathogenesis of 
these adverse events.
Although there is a theoretical concern re-
garding the use of immunosuppressive agents to 
manage the cytokine release syndrome or neuro-
logic events, the use of tocilizumab or glucocor-
ticoids did not appear to affect the overall response 
among the patients in our study. Furthermore, the 
development of a predictive or prognostic early 
Event Any Grade Grade 1 or 2 Grade ≥3
number of patients (percent)
Neurologic event
Any 65 (64) 37 (37) 28 (28)
Encephalopathy 34 (34) 13 (13) 21 (21)
Confusional state 29 (29) 20 (20) 9 (9)
Tremor 29 (29) 28 (28) 1 (1)
Aphasia 18 (18) 11 (11) 7 (7)
Somnolence 15 (15) 8 (8) 7 (7)
Agitation 9 (9) 5 (5) 4 (4)
Memory impairment 7 (7) 6 (6) 1 (1)
Mental-status change 6 (6) 4 (4) 2 (2)
*  Listed are adverse events that occurred in at least 30% of the patients, along with symptoms of the cytokine release 
syndrome and neurologic events that occurred in at least 5% of the patients. The cytokine release syndrome was cate-
gorized according to a modified grading system proposed by Lee et al.24 Individual symptoms of the cytokine release 
syndrome and neurologic events were graded according to the National Cancer Institute Common Terminology Criteria 
for Adverse Events, version 4.03.
Table 2. (Continued.)
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biomarker of the cytokine release syndrome or 
neurologic events may assist clinicians in deter-
mining when to intervene and optimize the 
management of toxic effects while preserving 
efficacy.
In conclusion, our findings support the use of 
axi-cel as an effective therapeutic option in adult 
patients with relapsed or refractory large B-cell 
lymphoma after at least two prior systemic thera-
pies. Adverse events included myelosuppression, 
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the cytokine release syndrome, and neurologic 
events.
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Figure 3 (facing page). CAR T-Cell Expansion and  
Correlations with Response and Adverse Events.
Serial blood samples were analyzed for chimeric anti-
gen receptor (CAR) T-cell levels and serum biomarkers 
in all 101 patients who were treated with axi-cel, as de-
scribed previously.21 Panel A shows CAR T-cell expan-
sion and persistence with median values and inter-
quartile ranges (Q1 and Q3). Panel B shows the 
association between CAR T-cell expansion, which was 
measured as peak levels of CAR cells per microliter of 
blood, and the objective response rate, neurologic 
events, and the cytokine release syndrome. The peak 
factor change is shown for patients with a response as 
compared with those without a response, for those 
with neurologic events of grade 3 or higher, and for 
those with the cytokine release syndrome of grade 3 
or higher. P values were calculated by means of the 
Wilcoxon rank-sum test. Panel C shows serum bio-
markers (interleukin-2, granulocyte–macrophage colo-
ny-stimulating factor [GM-CSF], and ferritin) that were 
associated only with neurologic events and not with 
the cytokine release syndrome. The peak value is de-
fined as the maximum level of the cytokine after base-
line. The peak factor is the value in patients with neu-
rologic events of grade 3 or higher versus those with 
events of grade 0 to 2. Adjusted P values were calcu-
lated with the use of Holm’s procedure after multiple 
testing by means of the Wilcoxon rank-sum test. In 
Panels B and C, the horizontal line within each box 
represents the median, and the lower and upper bor-
ders of each box represent the 25th and the 75th per-
centiles, respectively, and the I bars represent the 
minimum and maximum range.
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